Vigonvita Shanghai

Vigonvita is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for oncology and metabolic diseases. The company leverages its expertise in medicinal chemistry to target nuclear receptors and metabolic enzymes, with a primary focus on hormone-dependent cancers such as prostate and breast cancer. Its lead programs include next-generation androgen receptor antagonists and DHODH inhibitors. Vigonvita aims to address unmet medical needs through the development of highly potent and selective therapies with improved safety profiles compared to existing standards of care.